MedTrace Logo

Regadenoson R-T Perfusion Imaging Trial

NCT00837369 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-12-27

Study results available
· View outcomes & findings →

Summary

To exam the feasibility and accuracy of Regadenoson real time perfusion (RTPE) Imaging during vasodilator stress with Regadenoson for detection of significant coronary artery disease (CAD) in patients scheduled to undergo coronary angiography.

Conditions

Interventions

DRUG

Regadenoson

400ug IV bolus injection, single dosage

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Thomas R Porter, MD · University of Nebraska

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-07
Primary Completion
2011-03-01
Completion
2011-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837369 on ClinicalTrials.gov